Tesaro makes its case for a clean sweep with ni­ra­parib - and shares soar again

We al­ready knew go­ing in­to the big ES­MO meet­ing that Tesaro’s PARP in­hibitor ni­ra­parib had demon­strat­ed stel­lar re­sults for a range of ovar­i­an can­cer pa­tients with BR­CA mu­ta­tions. But when in­ves­ti­ga­tors stood up to dis­play the re­sults of their piv­otal study, a full set of da­ta demon­strat­ed a ben­e­fit not on­ly for tu­mors that were pos­i­tive for HRD, an im­por­tant bio­mark­er, but al­so for HRD-neg­a­tive tu­mors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER